Sun exec: Generic firms will face same tough times as innovators

High-flying Indian generics-maker Sun Pharmaceutical says it expects copycat companies to find themselves in the same uncomfortable position as cliff-hanging drug innovators are today beginning in 2015. Prepare for a struggle as fewer new treatments hit the market with their patent clocks ticking, says Sun chairman and managing director Dilip Shanghvi. His guidance: Copy what innovator drug companies do, not just what they make. Story

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.